Download presentation
Presentation is loading. Please wait.
Published byCatherine Leroux Modified over 5 years ago
1
Intralesional interferon alfa-2b for refractory, recurrent squamous cell carcinoma of the face
Allison Hanlon, MD, PhD, June Kim, MD, David J. Leffell, MD Journal of the American Academy of Dermatology Volume 69, Issue 6, Pages (December 2013) DOI: /j.jaad Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions
2
Fig 1 Recurrent, refractory squamous cell carcinoma (SCC) of the right lip. A, After the ninth recurrence, adjuvant intralesional interferon alfa-2b, 1.5 million U, was injected at multiple sites in the tumor periphery. The injection sites are marked by black dots. B, Twelve months after treatment, an SCC presented outside of the treatment field. There were no recurrences at the site. Journal of the American Academy of Dermatology , DOI: ( /j.jaad ) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.